PILOT STUDY OF INHALED NITRIC OXIDE IN PATIENTS WITH CYSTIC FIBROSIS

囊性纤维化患者吸入一氧化氮的试点研究

• 批准号: 7605076
• 负责人: Scott D SAGEL
• 金额: $ 0.78万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605076
• 关键词: Acute; Adult; Anti-Inflammatory Agents; Anti-inflammatory; Child; Chronic; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Funding; Grant; Institution; Lung; Lung diseases; Nitric Oxide; Persons; Pilot Projects; Pulmonary Cystic Fibrosis; Research; Research Personnel; Resources; Safety; Source; Therapeutic; United States National Institutes of Health; antimicrobial; cystic fibrosis patients; day; inhaled nitric oxide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nitric oxide (NO) is decreased in the airways of persons with cystic fibrosis (CF). Inhaled NO has the potential to be an effective treatment in CF lung disease, especially because of its anti-inflammatory and antimicrobial activities. The main objective of this initial project is to evaluate the safety and tolerability of inhaled NO over a 2 day period in older children and adults with CF. The long term objectives are to determine whether inhaled NO may be a useful therapeutic strategy for CF patients during an acute pulmonary exacerbation or even as a chronic therapy in CF patients with severe lung disease.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 囊性纤维化 (CF) 患者气道中的一氧化氮 (NO) 减少。 吸入一氧化氮有可能成为 CF 肺部疾病的有效治疗方法，特别是因为它具有抗炎和抗菌活性。 该初始项目的主要目标是评估患有囊性纤维化的年龄较大的儿童和成人在 2 天内吸入一氧化氮的安全性和耐受性。 长期目标是确定吸入 NO 是否可能是 CF 患者急性肺部恶化期间的有用治疗策略，或者甚至可以作为患有严重肺部疾病的 CF 患者的慢性治疗。